Generic drugs company HalcyGen Pharmaceuticals [ASX: HGN] has completed recruitment and dosing for the first of three pharmacokinetic trials of its SUBA-Itraconazole anti-fungal agent.

The trials, part of the company's Investigational New Drug (IND) application for the product, will examine the absorption, distribution, metabolism and excretion of SUBA-Itraconazole.

It will compare SUBA-Itraconazole directly to the itraconazole market-leader Sporanox, which was developed by Johnson and Johnson subsidiary Janssen Pharmaceuticals.

According to HalcyGen, early trials of SUBA-Itraconazole have already demonstrated increased bioavailability compared to Sporanox.